Results 241 to 250 of about 92,303 (298)

Establishment of ⁶⁸Ga-DOTA-Based Pretargeted Radioimmunodiagnosis. [PDF]

Mol Pharm
Veach DR, Burnes Vargas D, Islam B, Lee SG, Gajecki L, Vaughn BA, Yang G, Kalidindi TM, Pillarsetty NVK, Salehi N, Jaswal AP, Saha S, Le Roux AB, Xu H, Guo HF, Ouerfelli O, Cheung NV, Krebs S, Larson SM, Cheal SM.   +19 more
europepmc   +1 more source

First-In-Human Evaluation of [18F]Fluproxadine for Norepinephrine Transporter PET: Biodistribution, Dosimetry, and Safety. [PDF]

Clin Nucl Med
Yamane T, Iimori H, Akamatsu G, Ikari Y, Hoda Y, Shimizu K, Matsumoto K, Senda M, Werner RA, Nose N, Chen X, Higuchi T.   +11 more
europepmc   +1 more source

Single-Domain Antibody Probe with Low Renal Uptake for Claudin 18.2-Targeted PET Imaging of Gastric Cancer: Preclinical and Pilot Clinical Evaluations. [PDF]

J Nucl Med
Zheng M, Ma H, Xu T, Mu H, Liu Q, Zhang K, Bian Y, Zhang H, Li W, Zhang B, Shan Y, Peng X, Qin S, Wang Y, Miao L.   +14 more
europepmc   +1 more source

Toxicology and Biodistribution: The Clinical Value of Animal Biodistribution Studies [PDF]

Molecular Therapy - Methods and Clinical Development, 2018
Since the human genome decoding, understanding and identification of genetic disturbances behind many diseases, including cancer, are intensively increasing. Scientific and technological advances in this area trigger the search for therapeutic (curative) approaches targeting the correction of gene disturbances.
BEATRIZ Silva Lima
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Pharmacokinetics and Biodistribution of Nanoparticles

Molecular Pharmaceutics, 2008
Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs. The pharmacokinetics (PK) and tissue distribution of the nanoparticles largely define their therapeutic effect and toxicity.
Huan Xu, Shyh-Dar Li
exaly   +3 more sources

The biodistribution of metaiodobenzylguanidine

Seminars in Nuclear Medicine, 1992
M E T A I O D O B E N Z Y L G U A N I D I N E can be (MIBG) labeled with iodine-(123I) or 1311. The nearly ideal emission properties m a k e 1231 the preferred radionuclide? MIBG is a guanethidine analogue and was originally studied as a potential antihypertensive agent.
M T, Parisi, E D, Sandler, R S, Hattner
openaire   +2 more sources

Biodistribution of 59Fe-thiosemicarbazones

International Journal of Nuclear Medicine and Biology, 1982
The 59Fe-iron(II) chelates of 2-formylpyridine thiosemicarbazone (I), 5-dimethylamino-2-formylpyridine thiosemicarbazone (II), and 5-hydroxy-2-formylpyridine thiosemicarbazone (III) were prepared and their biodistribution determined in normal rats. Early accumulation of these complexes occurred in the liver, muscle and pelt with lesser amounts in the ...
R N, Hanson, M A, Davis
openaire   +2 more sources

Biodistribution of photosensitizing agents

International Journal of Biochemistry, 1993
1. The features of neoplasia which predict for drug responsiveness are rapid growth and/or inefficient repair of damage, especially to DNA. 2. PDT has the advantage of yielding responses regardless of the growth fraction of a tumor, and repair appears to play only a minor role. 3. While an entirely different spectrum of tumors can be targeted with PDT,
D, Kessel, K, Woodburn
openaire   +2 more sources

Allergen Biodistribution in Humans

2003
Specific immunotherapy performed by noninjectable (oral, nasal or oromucosal) routes was mostly developed in the last 20 years with the main aim to avoid side effects that occasionally occur in the course of injectable immunotherapy. Although evidence of its clinical efficacy has been provided some pharmacokinetics aspects are still to be elucidated ...
Bagnasco, Marcello, Morbelli, Silvia, Altrinetti, Vania, Falagiani, Paolo, Mariani, Giuliano, Passalacqua, Giovanni   +5 more
openaire   +4 more sources